Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John D Cook

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Biometrical Journal. Biometrische Zeitschrift|July 19, 2006
Stochastic inequality probabilities for adaptively randomized clinical trialsJohn D Cook, Saralees Nadarajah
Clinical Trials (London, England)|June 17, 2009
Bayesian design of single-arm phase II clinical trials with continuous monitoringValen E Johnson, John D Cook
Biometrics|September 2, 2004
Dose-finding based on efficacy-toxicity trade-offsPeter F Thall, John D Cook
Journal of Biopharmaceutical Statistics|March 22, 2017
Comparing three regularization methods to avoid extreme allocation probability in response-adaptive randomizationYining Du, John D Cook, J Jack Lee
Journal of Biopharmaceutical Statistics|October 14, 2006
Adaptive dose selection using efficacy-toxicity trade-offs: illustrations and practical considerationsPeter F Thall, John D Cook, Elihu H Estey
Statistics in Medicine|June 20, 2008
Dose--schedule finding in phase I/II clinical trials using a Bayesian isotonic transformationYisheng Li, B Nebiyou Bekele, Yuan Ji, et al.
Statistics in Medicine|October 24, 2007
Accounting for patient heterogeneity in phase II clinical trialsJ Kyle Wathen, Peter F Thall, John D Cook, et al.
Developmental Dynamics : an Official Publication of the American Association of Anatomists|January 28, 2004
Calcium transients regulate patterned actin assembly during myofibrillogenesisHongyan Li, John D Cook, Monica Terry, et al.
Stroke|July 12, 2008
Practical model-based dose finding in early-phase clinical trials: optimizing tissue plasminogen activator dose for treatment of ischemic stroke in childrenHarry T Whelan, John D Cook, Catherine M Amlie-Lefond, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2013
PI3K/mTOR inhibitor PF-04691502 antitumor activity is enhanced with induction of wild-type TP53 in human xenograft and murine knockout models of head and neck cancerAmanda Herzog, Yansong Bian, Robert Vander Broek, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Biometrical Journal. Biometrische Zeitschrift|July 19, 2006
Stochastic inequality probabilities for adaptively randomized clinical trialsJohn D Cook, Saralees Nadarajah
Clinical Trials (London, England)|June 17, 2009
Bayesian design of single-arm phase II clinical trials with continuous monitoringValen E Johnson, John D Cook
Biometrics|September 2, 2004
Dose-finding based on efficacy-toxicity trade-offsPeter F Thall, John D Cook
Journal of Biopharmaceutical Statistics|March 22, 2017
Comparing three regularization methods to avoid extreme allocation probability in response-adaptive randomizationYining Du, John D Cook, J Jack Lee
Journal of Biopharmaceutical Statistics|October 14, 2006
Adaptive dose selection using efficacy-toxicity trade-offs: illustrations and practical considerationsPeter F Thall, John D Cook, Elihu H Estey
Statistics in Medicine|June 20, 2008
Dose--schedule finding in phase I/II clinical trials using a Bayesian isotonic transformationYisheng Li, B Nebiyou Bekele, Yuan Ji, et al.
Statistics in Medicine|October 24, 2007
Accounting for patient heterogeneity in phase II clinical trialsJ Kyle Wathen, Peter F Thall, John D Cook, et al.
Developmental Dynamics : an Official Publication of the American Association of Anatomists|January 28, 2004
Calcium transients regulate patterned actin assembly during myofibrillogenesisHongyan Li, John D Cook, Monica Terry, et al.
Stroke|July 12, 2008
Practical model-based dose finding in early-phase clinical trials: optimizing tissue plasminogen activator dose for treatment of ischemic stroke in childrenHarry T Whelan, John D Cook, Catherine M Amlie-Lefond, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2013
PI3K/mTOR inhibitor PF-04691502 antitumor activity is enhanced with induction of wild-type TP53 in human xenograft and murine knockout models of head and neck cancerAmanda Herzog, Yansong Bian, Robert Vander Broek, et al.
Pageof 1